News
BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the leadership change ...
Ozempic made headlines. Now its maker faces stock crashes, CEO fallout, and fierce rivalry from Eli Lilly. Discover the trade behind the drama.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback